Journal
DIABETES & METABOLISM JOURNAL
Volume 45, Issue 3, Pages 326-336Publisher
KOREAN DIABETES ASSOC
DOI: 10.4093/dmj.2020.0272
Keywords
Diabetes mellitus; type 2; Lobeglitazone; Thiazolidinediones
Categories
Ask authors/readers for more resources
Lobeglitazone, a novel TZD, provides potent glycemic efficacy, low effective dose, and favorable safety results, with pleiotropic effects in preclinical and clinical studies. This drug was developed to address the demands for an effective and safe TZD in treating Type 2 diabetes mellitus.
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and beta-cell dysfunction. Among available oral antidiabetic agents, only the thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve insulin sensitivity by activating peroxisome proliferator-activated receptor gamma. Rosiglitazone and pioglitazone have been used widely for T2DM treatment due to their potent glycemic efficacy and low risk of hypoglycemia. However, their use has decreased because of side effects and safety issues, such as cardiovascular concerns and bladder cancer. Lobeglitazone (Chong Kun Dang Pharmaceutical Corporation), a novel TZD, was developed to meet the demands for an effective and safe TZD. Lobeglitazone shows similar glycemic efficacy to pioglitazone, with a lower effective dose, and favorable safety results. It also showed pleiotropic effects in preclinical and clinical studies. In this article, we summarize the pharmacologic, pharmacokinetic, and clinical characteristics of lobeglitazone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available